Jared Deck, MD
Radiation Oncology · Syracuse, NYNPI 1033609730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $744, 2.5 times the $296 reported in 2023.
Across 69 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$404
- Merck$223
- AbbVie$179
- Takeda Pharmaceuticals U.S.A., Inc.$133
- Reflexion Medical, Inc.$100
- Novocure Inc.$93
- plus $640 from 16 others
What the payments were for
- Food & beverage$1,72797%
- Education$453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $404 |
| Merck | 9 | $223 |
| AbbVie | 8 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $133 |
| Reflexion Medical, Inc. | 4 | $100 |
| Novocure Inc. | 1 | $93 |
| Geron Corporation | 3 | $75 |
| AstraZeneca | 3 | $71 |
| Karyopharm Therapeutics Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Incyte Corporation | 2 | $49 |
| Pfizer | 2 | $46 |
| Novartis | 2 | $41 |
| Puma Biotechnology, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Bayer | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Telix Pharmaceuticals | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$130
How this compares
$1,772 in reported general payments places this provider in the 75th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 13 | $293 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Syracuse
- Chung ChungSyracuse$3.1M
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Michael ZelefskyNew York$946K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.